Seminal Plasma Induces Prostaglandin-Endoperoxide Synthase (PTGS) 2 Expression in Immortalized Human Vaginal Cells: Involvement of Semen Prostaglandin E2 in PTGS2 Upregulation

Authors: Joseph, Theresa, Zalenskaya, Irina A., Sawyer, Lyn C., Chandra, Neelima, and Doncel, Gustavo F.

Source: Biology of Reproduction, 88(1)

Published By: Society for the Study of Reproduction

URL: https://doi.org/10.1095/biolreprod.112.101956
Seminal Plasma Induces Prostaglandin-Endoperoxide Synthase (PTGS) 2 Expression in Immortalized Human Vaginal Cells: Involvement of Semen Prostaglandin E2 in PTGS2 Upregulation

Theresa Joseph, Irina A. Zalenskaya, Lyn C. Sawyer, Neelima Chandra, and Gustavo F. Doncel

CONRAD, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia

ABSTRACT

Inflammation of the cervicovaginal mucosa is considered a risk factor for HIV infection in heterosexual transmission. In this context, seminal plasma (SP) may play an important role that is not limited to being the main carrier for the virions. It is known that SP induces an inflammatory reaction in the cervix called postcoital leukocytic reaction, which has been associated with promotion of fertility. The mechanisms by which SP triggers this reaction, however, have not been clearly established. Previously we reported the expression of prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cyclooxygenase 2 (COX-2), in human vaginal cells in response to toll-like receptor (TLR) ligands and other proinflammatory stimuli. In this study, we demonstrate that SP induces transcriptional and translational increase of COX-2 expression in human vaginal cells and cervicovaginal tissue explants. Furthermore, SP potentiates vaginal PTGS2 expression induced by other proinflammatory stimulants, such as TLR ligands and a vaginal mucosal irritant (nonoxynol-9) in a synergistic manner. SP-induced PTGS2 expression is mediated by intracellular signaling pathways involving MAPKs and NF-kB. Using fractionation and functional analysis, seminal prostaglandin (PG)-E2 was identified as a one of the major factors in PTGS2 induction. Given the critical role of this PG-producing enzyme in mucosal inflammatory processes, the finding that SP induces and potentiates the expression of PTGS2 in cervicovaginal cells and tissues has mechanistic implications for the role of SP in fertility-associated mucosal leukocytic reaction and its potential HIV infection-enhancing effect.

NF-kB, prostaglandin E2, PTGS2/COX-2, seminal plasma, sexually transmitted infections, toll-like receptors (TLRs), vaginal inflammation

INTRODUCTION

Mucosal inflammation of the female lower genital tract is regarded as an important factor favoring acquisition of HIV-1 infection via vaginal intercourse [1–3]. The sites of inflammation are enriched with HIV target immune cells and may have breaches in the mucosal epithelial barrier, both of which facilitate HIV acquisition [4]. Seminal plasma (SP) is the main vector for HIV in sexual transmission, but SP is not only a carrier for HIV [5, 6]. In vitro studies have shown that SP may both inhibit and facilitate HIV infection. Inhibitory effects of SP include antiviral activity of the semen cationic polypeptides, suppression of HIV binding to a subset of dendritic cells, protection of HIV-target cells by seminalogelin, inactivation of HIV by SP-reactive oxygen species, and SP-induced increase in transepithelial resistance [7–12]. In contrast, SP may facilitate HIV infection in several ways. Semen-derived enhancer of viral infection (SEVI) amyloid fibrils have been shown to promote virions’ attachment to target cells [13]. In cervicovaginal mucosa, SP induces upregulation of CCL20, a chemokine involved in attracting Langerhans cells to the epithelium, a phenomenon associated with HIV transmission [14]. Neutralization of the vaginal acidic pH, deleterious to virion survival, is an additional factor that increases the chances of HIV infection [15].

From in vivo studies, it is also known that semen causes the so-called postcoital inflammatory response, or leukocytic reaction [16, 17]. Presence of seminal plasma in the mammalian reproductive tract results in an immediate and dramatic influx of immune cells to the cervix and an increase in the level of proinflammatory cytokines and chemokines [18]. These changes are believed to play a role in facilitating conception [18, 19]. In immortalized cervical cells, SP has been reported to stimulate proinflammatory cytokines such as IL-8, IL-6, CSF2, CCL2, GM-CSF, and CCL20 [14, 20, 21].

SP has also been shown to induce prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cyclooxygenase 2 (COX-2), in cervical adenocarcinoma cells in vitro and ectocervical cells in vitro and in vivo [16, 20, 21]. PTGS2 codes for an enzyme that is ubiquitously expressed in inflammatory settings [22]. It catalyzes the rate-limiting step in the synthesis of prostaglandins. A major PTGS2 product, prostaglandin (PG) E2, is essential in inflammation-related tissue changes [23]. It induces vasodilation and increases vascular permeability, resulting in massive influx of immune cells, including HIV target cells, to the sites of inflammation. Elevated levels of PGE2 result in chemotraction and activation of immune cells and are associated with visible signs of acute inflammation [24]. Previously, we identified PTGS2 as a biomarker for vaginal inflammation. We have reported the induction of vaginal PTGS2 in response to diverse proinflammatory stimulants, such as TNF-α, microbial ligands, and cell membrane-damaging surfactants [25]. In this study, we demonstrate that SP causes PTGS2 upregulation in human vaginal cells, confirming the inflammatory potential of SP and suggesting a possible role in HIV-1 transmission. We also identify PGE2, abundantly present in SP, as one of the major factors responsible for PTGS2 induction in vaginal cells.
**MATERIALS AND METHODS**

**Materials**

Microbial ligands, Pam, CSK, (Pam) and Lipotetchoic acid (LTA), and the immunomodulatory compound imiquimod (IMQ) were purchased from Invivogen (San Diego, CA). Nonoxynol-9 (N-9) was a kind gift from OrthoMcNeil Corporation (Raritan, NJ). 16,16-dimethyl (dm) PGE2, and PGE2 receptor antagonist AH-6809 were purchased from Cayman chemical (Ann Arbor, MI). Signal transduction inhibitors Bayl1-7082, SB 202190, and U0126 were purchased from Calbiochem (Billerica, MA). Amicon Centrifugal Filter Devices with cutoffs of 100, 50, and 30 kD were purchased from Millipore Corporation (Billerica, MA). The primary antibodies used in the Western blot were anti-COX-2 (PTGS2; Abcam Inc., Cambridge, MA), anti-beta actin (ACTB; BD Transduction Labs, Chicago, IL), anti-phos p38MAPK (Bio-source, Grand Island, NY), anti-phos ERK1/2, anti-p38MAPK and anti-ERK 1/2 (Cell Signaling Technology, Boston, MA), anti-IkB-α and anti-NF-kBp65 (RE-LE; Santa Cruz Biotechnology, Santa Cruz, CA).

**Semen Collection and Preparation**

Human semen was obtained from healthy, normozoospermic men enrolled in an Eastern Virginia Medical School Institutional Review Board (IRB)-approved semen donation program. Sperm was left at room temperature for about 1 h to allow liquefaction to occur. The samples were then centrifuged at 4000 rpm for 20 min at room temperature. Samples were either used the same day or aliquoted and stored at −80°C. In some experiments, several samples were pooled. Some samples were purchased from Lee Biosolutions (St. Louis, MO).

**Seminal Plasma Fractionation and Heat Treatment**

To test for the heat lability of PTGS2-stimulating factor(s), SP was incubated at 95°C for 10 min. Molecular-weight fractionation of SP was done by sequential filtration of SP diluted in growth medium with Amicon Centrifugal Filter Devices with cutoffs of 100, 50, and 30 kD. All the retained and flow-through fractions were stored at −80°C until used.

**Cell Culture**

The vaginal epithelial cell line VK-2/E6E7 was a gift from Dr. Raina Fichorova (Brigham and Women’s Hospital, MA). This cell line was derived from epithelial cells of vaginal mucosal tissue from a 32-yr-old premenopausal woman undergoing anterior-posterior repair and was demonstrated to have structural and functional properties similar to those of their parental primary cells [26]. VK-2 cells were cultured to 80% confluency in 100- or 35-mm plates using keratinocyte serum-free medium (Gibco, Invitrogen, Grand Island, NY) supplemented with bovine pituitary extract (50 μg/ml) and epidermal growth factor at 0.1 ng/ml, penicillin-streptomycin (1%), and CaCl2 (0.4 mM). Medium was replenished every other day.

**Cytotoxicity**

Cells were grown in 96-well plates and incubated for 24 h with all the test compounds. Viability was estimated using CellTiter 96 AQ ueous One solution (Promega, Madison, WI).

**Electrophoresis and Immunoblotting**

Cells were washed three times with cold PBS and lysed with Laemmli loading buffer followed by boiling for 10 min to obtain total cellular protein. Nuclear and cytoplasmic fractions were isolated as described elsewhere [27] with minor modifications. Briefly, the cells were rinsed with ice-cold PBS and scraped with buffer containing 0.25 M sucrose, 10 mM Tris-HCl, pH 7.5, 3 mM CaCl2, and 0.5% Triton X-100. The samples were centrifuged at 1000 × g for 5 min. The supernatant and the pellet were the cytoplasmic and nuclear fractions, respectively.

These fractions were lysed using Laemmli loading buffer as mentioned above. Nuclear and cytoplasmic fractions were resolved by 10% SDS-polyacrylamide gel electrophoresis and transferred onto PVDF membrane (Immobilon-P; Millipore). Nonspecific binding was blocked for 1 h in PBS containing 0.1% Tween-20 and 5% nonfat dry milk for 1 h. The membrane was then washed and incubated with horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibody (Invitrogen). Immunodetection was performed using enhanced chemiluminescent Western blotting detection reagents (Amersham, GE Healthcare, Piscataway, NJ). To monitor protein loading for immunoblotting, the membrane was stripped, and ACTB, or p38MAPK or ERK 1/2, was detected. Immunoblots were visualized using FluorChem Q Imaging System (Alpha Innotech, San Leandro, CA). Quantification of the blots was done using Image J (National Institutes of Health, Bethesda, MD). Intensity of PTGS2 bands was quantified in arbitrary units by normalizing to ACTB.

**RNA Extraction and Quantitative RT-PCR**

Total RNA was isolated from cultured cells using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA) followed by purification using RNeasy columns (Qiagen, Valencia, CA) according to the manufacturer’s recommendations.

For quantitative PCR analysis, RNA (1 μg) was converted to cDNA using a combination of random primers (reverse transcription system; Promega). PCR amplification was performed using the LightCycler FastStart DNA Master SYBR Green I (Roche, Indianapolis, IN) kit, according to the manufacturer’s recommendations. GAPDH was used as the internal standard for PCR. The specific primers used were as follows:

<table>
<thead>
<tr>
<th>Gene (Forward/Reverse)</th>
<th>Sense/Reverse</th>
<th>Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTGS2: Forward 5'-TGAGCATCTACGGTTGCTG-3'</td>
<td>405</td>
<td>72°C, 1 min</td>
</tr>
<tr>
<td>Reverse 5'-TGCTTGCTGGAACAACTGC-3'</td>
<td>64°C, 1 min</td>
<td></td>
</tr>
<tr>
<td>GAPDH: Forward 5'-GATCCAGGATTTGGTCGT-3'</td>
<td>94°C, 1 min</td>
<td></td>
</tr>
<tr>
<td>Reverse 5'-GAATCAGGAGGCGCTCA-3'</td>
<td>64°C, 1 min</td>
<td></td>
</tr>
</tbody>
</table>

The thermocycler parameters were 95°C for 10 min, followed by 45 cycles of 95°C for 10 sec and 55°C for 5 sec and 72°C for 15 sec. Expression of PTGS2 mRNA was normalized using GAPDH. Relative gene expression was calculated by dividing the normalized expression in SP-treated cells by that of cells with growth medium only.

**Quantitation of PGE2**

SP PGE2 quantitation was done by multiple reaction monitoring (MRM) and liquid chromatography method using an ACQUITY UPLC system (Waters Corp., Milford, MA) at the Proteomics and Metabolomics Shared Resource, Lombardi Comprehensive Cancer Center of Georgetown University. (See description of procedure in Supplemental Materials and Methods, available online at www.biotechrepord.org.)

Each SP sample was prepared in triplicates, and three injections of each preparation were performed to assess reproducibility. The mass spectrometry data from the UPLC-TOFMS were processed using the TargetLynx (Waters Corp.).

**Ectocervical and Vaginal Tissue Culture and Sample Processing**

Ectocervical and vaginal tissues were obtained from premenopausal women (36 and 44 yr old, respectively) undergoing surgery because of benign gynecological conditions (fibroids and rectocele/cystocele). Proper consent was obtained according to an Eastern Virginia Medical School IRB-approved protocol. The mucosal and submucosal layers were dissected from the musculature. The tissues were cut into pieces 5 mm in diameter with 2–4 mm in thickness. They were acclimated at 37°C with 5% CO2 on cell culture inserts in RPMI 1640 (Invitrogen) supplemented with 10% FBS and penicillin-streptomycin (1%). Subsequently, the tissues were subjected to different treatments. For immunoblotting, proteins were solubilized by homogenization of tissues in Laemmlli loading buffer.

Immunohistochemistry (IHC) staining was performed with paraffin-embedded tissues fixed in 4% buffered formalin (Fisher Scientific, Hanover, NJ). Briefly, the slides were deparaffinized, dehydrated, and rehydrated as per standard procedures. This was followed by antigen retrieval in citrate buffer (pH 6.2) at high temperature. Thereafter, the slides were cooled and washed with PBS. This was followed by incubation with anti-COX-2 (PTGS2) primary antibody (Abcam) at 1:500 dilution. Nonspecific binding was blocked by 1.5% goat serum. The slides were washed and incubated with goat anti-rabbit biotinylated secondary antibody followed by ABC reagent (Vectorstain Labs, Burlingame, CA). The antigen was localized by incubation with AEC chromogen (ScyTek Labs, Logan, UT).

**Data Analysis and Statistics**

Statistical analysis and graphic presentation (Student t-test, Pearson correlation) were done using GraphPad Prism software version 5.0 (GraphPad Software, Inc., La Jolla, CA). P-values less than 0.05 were regarded statistically significant. Statistical significance is indicated in the legends to figures. Quantification of immunoblot was done using Image J software (National Institute of Health; Bethesda, MD).
Densitometric readings of PTGS2 signals on immunoblots were normalized to ACTB used as loading control and expressed in arbitrary units.

RESULTS

Effects of SP on Viability of Vaginal Cells

Human vaginal (VK-2/E6E7) cells were incubated with SP at different concentrations ranging from 0.1% to 30%. Viability was evaluated 24 h postincubation. A noticeable decrease in cell viability (down to 83% of medium control) was observed at a SP concentration of 20%, followed by a further drop in viability (to 65% of control) at a SP concentration of 30% (Fig. 1). Therefore, only SP concentrations ≤10% were used in the following experiments.

SP Induces a Dose-Dependent Increase in PTGS2 Expression in Human Vaginal Cells

Changes in PTGS2 mRNA and protein levels in vaginal cells in response to SP were assayed by quantitative RT-PCR and immunoblotting. Expression of PTGS2 followed a dose-dependent relationship with SP. The quantitative RT-PCR analysis revealed that PTGS2 mRNA expression increased 9-fold after treating the cells with 5% SP and 16-fold after treatment with 10% SP, compared to control (Fig. 2A). PTGS2 mRNA induction was corroborated by a similar dose-dependent increase in PTGS2 protein expression, as observed by immunoblotting (Fig. 2B).

SP Activates NF-κB and MAPK Pathways That Participate in PTGS2 Expression in Vaginal Cells

Depending on cell type and stimulus, different intracellular signaling pathways are shown to be involved in inflammation and PTGS2 expression. Nuclear factor kB (NF-κB) pathway is considered of central importance in inflammation and PTGS2 induction [28]. Activation of NF-κB in VK-2 cells stimulated with SP was demonstrated by rapid (within 30 min) degradation of NF-κB inhibitor IkB-α in cytoplasm accompanied by release and nuclear translocation of REL A (also known as NF-κB/p65; Fig. 3A). In addition, activation of mitogen-activated kinases (MAPK) p38 and ERK 1/2 was demonstrated by their phosphorylation, which occurred in VK-2 cells within 15 min of being incubated with SP (Fig. 3A). To confirm the involvement of these pathways in PTGS2 expression, VK-2 cells were treated with the pathway-specific

FIG. 1. Dose-dependent cytotoxicity of SP. VK-2 cells were treated for 24 h with SP at concentrations ranging from 0.1% to 30% v/v in culture medium. Viability was measured by CellTiter 96 AQufix One solution Cell Proliferation assay (Promega). Viability of SP-treated cells was estimated in relation to the viability of the cells treated with culture medium alone taken as 100%. Results are expressed as mean ± SD of three independent experiments.

FIG. 2. SP stimulates transcriptional and translational PTGS2 expression in VK-2 cells in a dose-dependent manner. VK-2 cells grown in 35-mm plates were treated with 0.1–10% SP for 24 h and assayed for PTGS2 expression. A) PTGS2 mRNA upregulation was assayed by quantitative RT-PCR. GAPDH was used as a normalizing gene. Results are expressed as the mean ± SD of multiple experiments. **P < 0.01. B) PTGS2 protein expression was assayed by immunoblotting. ACTB was used as a loading control.

FIG. 3. MAPK and NF-κB pathways are involved in SP-induced PTGS2 expression. VK-2 cells grown in 100-mm plates were treated with 10% SP for indicated time. A) Nuclear fractions were assayed for REL A translocation; cytoplasmic fractions were assayed for IkB-α degradation; whole cell lysates were assayed for phosphorylation of ERK1/2 and p38MAPK by immunoblotting. B) Immunoblots of PTGS2 expression in VK-2 cells treated with SP in the presence or absence of the indicated pathway-specific inhibitors for 6 h; ACTB was used as a loading control.
inhibitors Bay11-7082 (NF-κB pathway), SB202190 (p38MAPK), and U0126 (ERK 1/2). Presence of each of the inhibitors abolished expression of PTGS2 (Fig. 3B), confirming the pathway involvement in SP induced PTGS2 expression by vaginal cells.

**SP Potentiates PTGS2 Expression Caused by TLR Ligands and N-9**

We previously demonstrated that TLR ligands Pam, LTA, and IMQ and the proinflammatory surfactant N-9 induce PTGS2 expression in VK-2 cells [25, 29]. In this study, we evaluated the effect of SP on PTGS2 expression in the presence of these compounds. Suboptimal concentrations of the compounds and SP dilutions were selected so that individual treatments of cells would result in low to negligible expression of PTGS2. However, when the compounds and SP were combined at these concentrations, PTGS2 protein expression was much higher than a mere sum of the PTGS2 induced by either of the treatments (Fig. 4). The observed synergistic effect of SP and TLR ligands implies that exposure to SP could potentiate inflammatory responses of the female vaginal epithelium to microbial antigens.

**SP from Different Individuals Shows Variability in Its Capacity to Induce PTGS2 Expression**

To evaluate interindividual variability in SP capacity to induce PTGS2, VK-2 cells were treated with SP from 12 different donors. Figure 5 shows a considerable interindividual variation in PTGS2 mRNA induction as demonstrated by quantitative RT-PCR. A mean of 24-fold increase in PTGS2

---

**FIG. 4.** SP induces expression of PTGS2 in synergy with other pro-inflammatory stimuli. VK-2 cells grown in 35-mm plates were treated with SP and proinflammatory stimuli for 24 h. Expression of PTGS2 was assayed by immunoblotting, ACTB was used as a loading control (A). Bacterial lipopeptides Pam and LTA were used at concentrations of 5 and 10 μg/ml, respectively, in the presence of 1% SP. B) Inflammatory compounds N-9 and IMQ were used at concentrations of 6 and 10 μg/ml in the presence of 3% SP. The graph below each blot shows the band intensity of PTGS2 expressed in arbitrary units, normalized to ACTB. Values were obtained from densitometric readings using Image J.
expression was observed across the group with donor-to-donor variation ranging from 7.4- to 41.6-fold compared to control (Fig. 5). Variations (although not as high in magnitude) in the PTGS2 stimulatory effect were also observed between semen samples from the same donor obtained on different days (data not shown).

**PGE$_2$ Is a Major Factor in SP-Mediated Stimulation of PTGS2**

In an initial step to characterize the factor(s) responsible for PTGS2 induction, SP was heated for 10 min at 95°C. Figure 6A demonstrates that heat treatment drastically decreased the capacity of SP to induce PTGS2 in VK-2 cells, suggesting that the SP factor(s) responsible for increasing PTGS2 production was heat labile.

Next, SP was fractionated on the basis of the the molecular weights of its constituents using Amicon Centrifugal Filters with cutoffs of 100, 50, and 30. VK-2 cells were then treated with filter-retained and flow-through fractions. Fractions that passed through the filters with a cutoff of 30 kDa remained active in PTGS2 induction. In contrast, the retained fractions did not cause PTGS2 expression. Notably, although flow-through lower-molecular-weight fractions were free from higher-molecular-weight proteins, the separation was not complete for the retained fractions. Small proteins, similar to those contained in the flow-through fractions, were still present in the retained fractions (observed by gel electrophoresis), while PTGS2-stimulating activity was lost in them, suggesting that PTGS2 was induced by small nonprotein molecules present in the flow-through fraction. PGE$_2$ is a biologically active, heat-labile, small molecule (molecular weight = 352.5 Da) that is present in high quantity in SP [30]. Importantly, PGE$_2$ is known to stimulate PTGS2 expression in various cells, including cervical adenocarcinoma cells [21]. We hypothesized that PGE$_2$ could be the factor responsible for PTGS2 induction.

To test this hypothesis, VK-2 cells were treated with PGE$_2$ receptor antagonist AH 6809, which has equal affinity to multiple PGE$_2$ receptors [31]. SP induction of PTGS2 was completely inhibited in the presence of the PGE$_2$ receptor antagonist. Furthermore, we confirmed the stimulatory activity...
of PGE₂ by testing dmPGE₂ (a stable form of PGE₂), which caused a dose-dependent increase in PTGS2 expression in VK-2 cells (Fig. 6D).

**PGE₂ Levels in Seminal Plasma Correlate with Seminal Plasma Ability to Stimulate PTGS2 Expression in VK-2 Cells**

PGE₂ was quantified in several individual SP samples showing distinctly high or low PTGS2 induction capacity using liquid chromatography (Fig. 7, A and B). PTGS2 protein levels in VK-2 cells were evaluated by PTGS2 immunoblot band intensities normalized to ACTB. A positive correlation (Pearson correlation coefficient \( R^2 = 0.89, P = 0.016 \)) between the concentration of PGE₂ and PTGS2 levels was observed (Fig. 7C), supporting the hypothesis that PGE₂ in SP is implicated in PTGS2 induction in vaginal epithelial cells.

**SP Induces PTGS2 Expression in Ectocervical and Vaginal Tissue Explants**

Next, we verified the expression of PTGS2 in response to SP in ectocervical tissue explants. Cultured cervical tissues were treated with pooled SP at 75% in medium for 24 h. A clear increase in PTGS2 protein expression was observed by IHC staining (Fig. 8A) and was further corroborated by immunoblotting using anti-PTGS2 antibodies (Fig. 8B). Similar results indicating increase in PTGS2 expression were obtained for vaginal explants treated with 75% SP for 24 h (Fig. 9).

**DISCUSSION**

Earlier, we reported that diverse proinflammatory stimuli cause expression of PTGS2 in human vaginal epithelial cells [25, 29]. PTGS2 (or COX-2) is an inducible enzyme that is essential in promoting inflammation [32–34]. It catalyzes the rate-limiting step in the synthesis of prostaglandins. A major PTGS2 product, PGE₂, is considered to be the primary culprit of inflammation-related changes in tissues [23]. Here, we report that SP causes transcriptional and translational dose-dependent induction of PTGS2 in human vaginal epithelial cells.

SP induction of PTGS2 in the female genital tract has been demonstrated in endometrial tissues of horses and pigs and in human cervical adenocarcinoma cells [21, 35, 36]. More recently, SP-induced PTGS2 expression was also observed in normal cervical biopsies as part of an inflammatory-like response postulated to be necessary for promotion of fertility [16, 20].

One of the central pathways involved in cellular inflammatory responses and PTGS2 upregulation is the NF-kB signaling pathway. In addition, different MAPKs may also be activated in response to proinflammatory stimuli and engaged in PTGS2 expression [37]. Previously, we have reported that NF-kB and MAPK pathways are involved in PTGS2 expression in vaginal cells in response to the proinflammatory spermicide N-9 [25]. We also found that these pathways are implicated in PTGS2 upregulation via TLRs stimulated by microbial pathogens (unpublished results). Here, we demonstrate that the same
signaling pathways, NF-kB, p38MAPK, and ERK1/2, are also activated by SP and that their activation is responsible for PTGS2 induction (Fig. 3).

Given the commonality in induction pathways, we wanted to evaluate the impact of SP on PTGS2 expression in the presence of other proinflammatory stimuli commonly present in the vaginal environment. We found that SP acts in synergy with TLR ligands, such as Pam, LTA, and IMQ and the vaginal spermicide N-9. We demonstrated that PTGS2 expression induced by these compounds is strongly potentiated by SP.

FIG. 8. SP induces PTGS2 in ectocervical tissue explants in culture. Ectocervical tissues were treated with SP (75%) for 24 h. PTGS2 expression was assayed by (A) IHC and (B) immunoblotting; ACTB was used as a loading control. GM, growth medium. Original magnification ×400.

FIG. 9. SP induces PTGS2 in vaginal tissue explants in culture. Vaginal tissues were treated with SP (75%) for 24 h. PTGS2 expression was assayed by IHC. Original magnification ×400.
These data imply that, in vivo, SP could favor or increase inflammatory responses triggered by preexisting cervicovaginal infections. In addition, SP from men harboring genital infections could be more potent in eliciting inflammatory responses in the female genital mucosa than SP from healthy men. This is in agreement with reports of higher incidences of cervicitis in women whose partners are diagnosed with urethritis [38, 39]. Furthermore, our data suggest that exposure to SP in sexually active women may worsen mucosal inflammation caused by vaginal topical products, such as those containing N-9 (commercial spermicides) or IMQ (products to treat genital/anal warts) as active ingredients. Tested in a phase III clinical trial as an HIV microbicide, N-9 not only failed to protect women but actually increased susceptibility to HIV infection if used frequently [40]. Cervicovaginal mucosal inflammation induced by frequent exposure to N-9 has been postulated as a causative factor for the observed increased rate of HIV infection [41, 42]. Our data further suggest that frequent exposure to SP in this population of commercial sex workers could have exacerbated N-9-induced inflammatory response, thus increasing the propensity for HIV infection.

We have observed considerable variation in the PTGS2-inducing capacity of SP among different individuals (Fig. 5), which could be the result of interindividual variability in SP composition [43, 44]. We have also noted some variation among SP samples from the same individual. SP variability could be due to differences in genetic polymorphisms, lifestyle, sexual practices, and use of medications [45]. Other significant factors are subclinical infections and variations in the genital microbiome. Seasonal variations due to changes in daylight and temperature could in turn explain the differences in SP from the same person [45, 46].

Semen plasma is a complex fluid that contains a multitude of biologically active molecules [43]. In our attempts to pinpoint the factor(s) responsible for PTGS2 stimulation, we found that small molecules, possibly of a nonprotein nature, might be plausible candidates (Fig. 6A). We hypothesized that these could be prostaglandins of the E-series, which are present in SP at uniquely high concentration (of at least three orders of magnitude higher than in other human fluids and tissues) [30]. PGE2 mediates its activity through four subtypes of G-protein-coupled receptors, EP1–EP4 [33]. We demonstrated that PTGS2 expression was abrogated in the presence of AH-6809, an antagonist of prostaglandin receptors that blocks EP1, EP2, and EP3. AH-6809 also suppresses receptor of PGD2 [31]; however PGD2 is not present in SP, which justifies the suggestion that the prostaglandin(s) involved in PTGS2 induction by SP belong to PGE family (Fig. 6C). One of the most important PGEs known to be involved in inflammation is PGE2, a low-molecular-weight (352.5 Da) component present in SP. Importantly, being a product of PTGS2 activity, PGE2 promotes replication of the virus [49] and activates HIV-1 long terminal repeat (LTR)-mediated gene activity in T-cells [50]. Activation of HIV-LTR was also observed in the presence of SP [11]. This would point to a direct effect of SP in promoting HIV infection, separate from the reported facilitating effect of SP-derived amyloid fibrils [13, 51].

Furthermore, SP may also facilitate HIV infection indirectly. Involvement of PGE2 in inflammation is well established. Acting via EP receptors, PGE2 is capable of modulating the immune cells functions, and their activation might increase HIV-1 capture, transmission, and/or infection. A novel role of PGE2 in immune activation as a factor that facilitates expansion of Th17 subset of T helper cells is now emerging [52]. Importantly, evidence is accumulating that Th17 cells are preferential targets for HIV-1/SIV [53, 54].

Recently, another molecule, transforming growth factor-β (TGF-β), which is present in extremely high concentration in human semen, has been shown to induce activation of a number of inflammation-related genes, including PTGS2 in the female genital tract [55]. There are three isoforms of TGF-β in semen (TGF-β1, TGF-β2, TGF-β3); they exist predominantly in a latent form complexed with the latency-associated peptide (LAP). Physiological release from an inactive complex can be accomplished by proteolytic degradation of LAP. Physicochemical activation of TGF-β can be achieved by heat. Maximum activation of TGF-β2 and TGF-β3 occurs at 100°C, while TGF-β1 is denatured at this temperature [56]. Heat-activated TGF-β isoforms can account for PTGS2-inducing activity that we observed in vaginal cells treated with thermally treated SP (Fig. 6). It has been proposed that TGF-β can interact with PGEs to cause inflammation-related response [55].

It has been known for several decades that SP causes an inflammatory-like response in the female genital mucosa [18]. Increased migration of immune cells to the site of semen deposition, called leukocytic reaction [17, 57], and expression and release of diverse proinflammatory cytokines stimulated by SP have been observed in different mammals, including humans [58]. It has been proposed that these events facilitate conception [18]. While being physiologically beneficial for reproductive functions, the influx of immune cells that are targets for HIV infection may enhance HIV acquisition and transmission.

In conclusion, seminal plasma induces PTGS2 in vaginal epithelial cells through activation of NF-κB and MAPKs. SP-induced PTGS2 expression follows a specific and dose-dependent response and shows interindividual variability. Semen PGE2 is involved in the PTGS2 induction. Increased mucosal expression of PTGS2, especially in the presence of microbial antigens and other proinflammatory stimuli, may have implications for HIV-1 transmission and the design of strategies to prevent sexually transmitted infections.

ACKNOWLEDGMENT

The authors would like to thank Dr. Amrita Cheema and her team at Proteomics and Metabolomics Shared Resource, Lombardi Comprehensive Cancer Center of Georgetown University, for quantitation of PGE2 in seminal plasma.

REFERENCES


